NuCana (NCNA) Intangibles (2015 - 2025)
NuCana (NCNA) reported Intangibles of $2.9 million for Q4 2025, up 3.59% on a YoY basis from $2.8 million in Q4 2024, and down 1.38% sequentially from $3.0 million in Q3 2025.
NuCana (NCNA) Intangibles (2015 - 2025) Analysis & Trends
NuCana (NCNA) has 11 years of Intangibles data on file, last reported at $2.9 million in Q4 2025.
- For the quarter ending Q4 2025, Intangibles rose 3.59% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (up 3.59% YoY), and the FY2025 full-year result was $2.9 million, up 3.1% from the prior year.
- Intangibles fell to $2.9 million in Q4 2025, from $3.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $9.8 million in Q4 2023 to a low of -$6.0 million in Q4 2021.
- A 5-year average of $3.7 million and a median of $3.0 million in 2025 frame the typical range for Intangibles.
- Across the five-year window, Intangibles tumbled 178.33% in 2021 and soared 242.9% in 2022, its largest moves.
- Tracing NCNA's Intangibles over 5 years: stood at -$6.0 million in 2021, then surged by 242.9% to $8.6 million in 2022, then advanced by 14.89% to $9.8 million in 2023, then sank by 71.27% to $2.8 million in 2024, then rose by 3.59% to $2.9 million in 2025.
- Business Quant data shows NCNA's Intangibles at $2.9 million in Q4 2025, $3.0 million in Q3 2025, and $2.9 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 11,640.44 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 61.68 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.92 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 266.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 55.80 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.92 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Jun 30, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.76 Mn |
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 2.90 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 2.75 Mn |
| Dec 31, 2023 | 9.82 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 3.19 Mn |
| Mar 31, 2023 | 3.01 Mn |
| Dec 31, 2022 | 8.55 Mn |
| Sep 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | -5.98 Mn |
| Sep 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | 6.73 Mn |
| Mar 31, 2021 | 6.57 Mn |